Next Article in Journal
It Is High Time for Personalized Dietary Counseling in Celiac Disease: A Systematic Review and Meta-Analysis on Body Composition
Next Article in Special Issue
Nuts: Natural Pleiotropic Nutraceuticals
Previous Article in Journal
Nutritional, Anthropometric and Sociodemographic Factors Affecting Fatty Acids Profile of Pregnant Women’s Serum at Labour—Chemometric Studies
Previous Article in Special Issue
Urinary Tartaric Acid, a Biomarker of Wine Intake, Correlates with Lower Total and LDL Cholesterol
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 13
Issue 9
10.3390/nu13092957
Review Report
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

Printed Edition

A printed edition of this Special Issue is available at MDPI Books....
share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice

Nutrients 2021, 13(9), 2957; https://doi.org/10.3390/nu13092957
by Peter E. Penson 1,2 and Maciej Banach 3,4,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Nutrients 2021, 13(9), 2957; https://doi.org/10.3390/nu13092957
Submission received: 4 August 2021 / Revised: 21 August 2021 / Accepted: 22 August 2021 / Published: 25 August 2021
(This article belongs to the Special Issue Nutraceutical Approaches to Cardiovascular and Metabolic Diseases: Evidence and Opportunities)

Round 1

Reviewer 1 Report

The manuscript by Penson and Banach is an effective high-level literature review (position paper and recommendations from the International Lipid Expert Panel) on the use of nutraceuticals in clinical practice.
This work is important in light of the fact that in the International Guidelines (ESC / EAS 2019) little space is reseved to dietary and nutraceutical therapies, while in patients with low cardiovascular risk and intolerant / refusing statins, they can represent the cornerstone of lipid-lowering therapy. The revision is well done.
Perhaps something more extended could be added about berberine which has shown lipid-lowering nutraceutical efficacy documented in some studies, even if more limited.

Author Response

Response to Reviewer: 

Thank you for your positive feedback on our paper. Thank you for your suggestion on berberine. Its role has been already strongly emphasized in all cited ILEP recommendations. Here in this paper we focused on those three with the largest EBM (including CVOT data), as well as those already mentioned in European recommendations. Adding more data on berberine would mean we should do the same for the other well-recognized like policosanol, bergamot, curcumin, sterols, etc. Therefore, we would like to stay with the current version of the paper, if it is acceptable. 

Reviewer 2 Report

The review “Nutraceuticals for the control of dyslipidemias in clinical practice” summarizes recent clinical-practice guidance related to the use of nutraceuticals for the control of hyperlipidemia. Particular attention is given to position papers and recommendations from the International Lipid Expert Panel (ILEP), which has produced several practical and helpful recommendations in this field.

 

The article is appropriately organized and well written.

 

I suggest the correction of minor mispellings as

Line 72: The term “nutraceutical” was…

Line 139: 3.2.ω3 fatty acids

Line 264-265: please rephrase the sentence

Author Response

Thank you for all your valuable comments. We have revised the text accordingly. 

Back to TopTop